Over the last 12 months, six Scribe Therapeutics, Inc. executives and directors bought into shares with their own money, about $71.3 million in total, and none of them sold.
Avoro Ventures LLC (Director) made the biggest buy, worth around $35 million. Notably, at least one C-suite executive was among the buyers.
Zooming out by quarter: Last full quarter: net buying by insiders. Insiders bought in 1 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Jul 29, 2026 | AH Equity Partners Bio II, L.L.C. | 10% Owner | Buy | 333,333 | $15.00 | $5.0M | SEC |
| Jul 29, 2026 | GORDON CARL L | Director | Buy | 1,000,000 | $15.00 | $15.0M | SEC |
| Jul 29, 2026 | ORBIMED ADVISORS LLC | Director | Buy | 1,000,000 | $15.00 | $15.0M | SEC |
| Jul 28, 2026 | Avoro Ventures LLC | Director | Buy | 7,905 | $18.25 | $144K | SEC |
| Jul 28, 2026 | Avoro Ventures LLC | Director | Buy | 50,000 | $22.31 | $1.1M | SEC |
| Jul 28, 2026 | Avoro Ventures LLC | Director | Buy | 2,333,333 | $15.00 | $35.0M | SEC |
| Jul 27, 2026 | Lucas Svetlana | Executive Officer | Buy | 3,000 | $15.00 | $45K | SEC |
| Jul 27, 2026 | Parrot David | CFO | Buy | 1,333 | $15.00 | $20K | SEC |
| Jul 27, 2026 | Parrot David | CFO | Buy | 1,333 | $15.00 | $20K | SEC |
In the last 12 months Scribe Therapeutics, Inc. insiders made open-market purchases worth about $71.3 million and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in SCTX was filed on 2026-07-29.
No congressional trades in SCTX were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).